Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagicBullet: Colistin vs Meropenem in VAP
NCT01292031Phase 3Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- May 2012
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of colistin in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Number of patients who die at 28 days. Started May 2012; status: completed.
02
Drugs
colistin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT01292031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292031.